BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kotecha D, Bunting KV, Gill SK, Mehta S, Stanbury M, Jones JC, Haynes S, Calvert MJ, Deeks JJ, Steeds RP, Strauss VY, Rahimi K, Camm AJ, Griffith M, Lip GYH, Townend JN, Kirchhof P; Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) Team. Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial. JAMA 2020;324:2497-508. [PMID: 33351042 DOI: 10.1001/jama.2020.23138] [Cited by in Crossref: 51] [Cited by in F6Publishing: 31] [Article Influence: 25.5] [Reference Citation Analysis]
Number Citing Articles
1 Garg J, Gopinathannair R, Lakkireddy D. Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation. JAMA 2021;325:1680-1. [PMID: 33904875 DOI: 10.1001/jama.2021.2673] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Alobaida M, Alrumayh A. Rate control strategies for atrial fibrillation. Ann Med 2021;53:682-92. [PMID: 34032538 DOI: 10.1080/07853890.2021.1930137] [Reference Citation Analysis]
3 McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; Authors/Task Force Members:., ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4-131. [PMID: 35083827 DOI: 10.1002/ejhf.2333] [Cited by in Crossref: 124] [Cited by in F6Publishing: 33] [Article Influence: 124.0] [Reference Citation Analysis]
4 Karwath A, Bunting KV, Gill SK, Tica O, Pendleton S, Aziz F, Barsky AD, Chernbumroong S, Duan J, Mobley AR, Cardoso VR, Slater L, Williams JA, Bruce EJ, Wang X, Flather MD, Coats AJS, Gkoutos GV, Kotecha D; card AIc group and the Beta-blockers in Heart Failure Collaborative Group. Redefining β-blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis. Lancet 2021;398:1427-35. [PMID: 34474011 DOI: 10.1016/S0140-6736(21)01638-X] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Trongtorsak A, Kewcharoen J, Saowapa S, Polpichai N, Thangjui S, Navaravong L. Comparison of mortality rates among rate-control agents in patients with atrial fibrillation: a systematic review and meta-analysis. J Cardiovasc Med (Hagerstown) 2022;23:e39-41. [PMID: 34860198 DOI: 10.2459/JCM.0000000000001283] [Reference Citation Analysis]
6 Kytö V, Saraste A, Rautava P, Tornio A. Digoxin use and outcomes after myocardial infarction in patients with atrial fibrillation. Basic Clin Pharmacol Toxicol 2022;130:655-65. [PMID: 35420260 DOI: 10.1111/bcpt.13733] [Reference Citation Analysis]
7 Metzner A, Suling A, Brandes A, Breithardt G, Camm AJ, Crijns HJGM, Eckardt L, Elvan A, Goette A, Haegeli LM, Heidbuchel H, Kautzner J, Kuck KH, Mont L, Ng AA, Szumowski L, Themistoclakis S, van Gelder IC, Vardas P, Wegscheider K, Willems S, Kirchhof P. Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST - AFNET 4 trial. Europace 2021:euab200. [PMID: 34473249 DOI: 10.1093/europace/euab200] [Reference Citation Analysis]
8 McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599-726. [PMID: 34447992 DOI: 10.1093/eurheartj/ehab368] [Cited by in Crossref: 209] [Cited by in F6Publishing: 73] [Article Influence: 209.0] [Reference Citation Analysis]
9 Wintrich J, Abdin A, Böhm M. Management strategies in heart failure with preserved ejection fraction. Herz 2022. [PMID: 35524007 DOI: 10.1007/s00059-022-05119-5] [Reference Citation Analysis]
10 Reddy YNV, Borlaug BA, Gersh BJ. Management of Atrial Fibrillation Across the Spectrum of Heart Failure With Preserved and Reduced Ejection Fraction. Circulation 2022;146:339-57. [PMID: 35877831 DOI: 10.1161/CIRCULATIONAHA.122.057444] [Reference Citation Analysis]
11 Mcdonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JG, Coats AJ, Crespo-leiro MG, Farmakis D, Gilard M, Heyman S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CS, Lyon AR, Mcmurray JJ, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GM, Ruschitzka F, Skibelund AK. Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. Revista Española de Cardiología 2022. [DOI: 10.1016/j.recesp.2021.11.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Baker WL, Sobieraj DM, DiDomenico RJ. Influence of digoxin on mortality in patients with atrial fibrillation: Overview of systematic reviews. Pharmacotherapy 2021;41:394-404. [PMID: 33544894 DOI: 10.1002/phar.2510] [Reference Citation Analysis]
13 Ren J, Gao X, Guo X, Wang N, Wang X. Research Progress in Pharmacological Activities and Applications of Cardiotonic Steroids. Front Pharmacol 2022;13:902459. [PMID: 35721110 DOI: 10.3389/fphar.2022.902459] [Reference Citation Analysis]
14 Kempf T, Bauersachs J, Bavendiek U. Eisen und Digitalis bei Herzinsuffizienz. Aktuelle Kardiologie 2021;10:302-9. [DOI: 10.1055/a-1472-0114] [Reference Citation Analysis]
15 Meyer M, Du Fay Lavallaz J, Benson L, Savarese G, Dahlström U, Lund LH. Association Between β-Blockers and Outcomes in Heart Failure With Preserved Ejection Fraction: Current Insights From the SwedeHF Registry. J Card Fail 2021:S1071-9164(21)00158-5. [PMID: 33971289 DOI: 10.1016/j.cardfail.2021.04.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Chrysant SG, Chrysant GS. Antihypertensive and cardioprotective effects of three generations of beta-adrenergic blockers: an historical perspective. Hosp Pract (1995) 2022. [PMID: 35157531 DOI: 10.1080/21548331.2022.2040920] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Kotecha D. Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation-Reply. JAMA 2021;325:1681-2. [PMID: 33904873 DOI: 10.1001/jama.2021.2676] [Reference Citation Analysis]
18 Ding WY, Boriani G, Marin F, Blomström-Lundqvist C, Potpara TS, Fauchier L, Lip GYH. Outcomes of digoxin vs. beta-blocker in AF: report from ESC-EHRA EORP-AF Long-Term General Registry. Eur Heart J Cardiovasc Pharmacother 2021:pvab076. [PMID: 34665249 DOI: 10.1093/ehjcvp/pvab076] [Reference Citation Analysis]
19 Zhao S, Li X, Wu W, Liu S, Shen M, Zhang Z, He J. Digoxin reduces the incidence of prostate cancer but increases the cancer-specific mortality: A systematic review and pooled analysis. Andrologia 2021;53:e14217. [PMID: 34414594 DOI: 10.1111/and.14217] [Reference Citation Analysis]
20 Schleberger R, Rillig A, Kirchhof P, Metzner A, Reissmann B. [Update atrial fibrillation: the 2020 ESC guidelines and recent data on early rhythm control]. Herzschrittmacherther Elektrophysiol 2021;32:257-63. [PMID: 33783622 DOI: 10.1007/s00399-021-00749-4] [Reference Citation Analysis]
21 Volgman AS, Nair G, Lyubarova R, Merchant FM, Mason P, Curtis AB, Wenger NK, Aggarwal NT, Kirkpatrick JN, Benjamin EJ. Management of Atrial Fibrillation in Patients 75 Years and Older: JACC State-of-the-Art Review. J Am Coll Cardiol 2022;79:166-79. [PMID: 35027110 DOI: 10.1016/j.jacc.2021.10.037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
22 Bisson A, Ding WY, Bodin A, Lip GYH, Fauchier L. Clinical outcomes with digoxin vs. beta-blocker for heart rate control in permanent atrial fibrillation with heart failure. Eur J Heart Fail 2021. [PMID: 34231295 DOI: 10.1002/ejhf.2292] [Reference Citation Analysis]
23 Zhou H, Yao M, Gu X, Liu M, Zeng R, Li Q, Chen T, He W, Chen X, Yuan G. Application of Patient-Reported Outcome Measurements in Clinical Trials in China. JAMA Netw Open 2022;5:e2211644. [PMID: 35544134 DOI: 10.1001/jamanetworkopen.2022.11644] [Reference Citation Analysis]
24 Phillips K, Subramanian A, Thomas GN, Khan N, Chandan JS, Brady P, Marshall T, Nirantharakumar K, Fabritz L, Adderley NJ. Trends in the pharmacological management of atrial fibrillation in UK general practice 2008-2018. Heart 2021:heartjnl-2021-319338. [PMID: 34226195 DOI: 10.1136/heartjnl-2021-319338] [Reference Citation Analysis]
25 Fauchier L, Boriani G, de Groot JR, Kreutz R, Rossing P, Camm AJ. Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus. Europace 2021;23:1873-91. [PMID: 34411235 DOI: 10.1093/europace/euab184] [Reference Citation Analysis]
26 Goldwater D, Wenger NK. Patient-centered care in geriatric cardiology. Trends Cardiovasc Med 2021:S1050-1738(21)00129-8. [PMID: 34758389 DOI: 10.1016/j.tcm.2021.11.001] [Reference Citation Analysis]
27 Wang X, Luo Y, Xu D, Zhao K. Effect of Digoxin Therapy on Mortality in Patients With Atrial Fibrillation: An Updated Meta-Analysis. Front Cardiovasc Med 2021;8:731135. [PMID: 34660731 DOI: 10.3389/fcvm.2021.731135] [Reference Citation Analysis]
28 Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology 2022. [DOI: 10.1016/j.jacc.2021.12.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 27.0] [Reference Citation Analysis]
29 Bunting KV, Stanbury M, Tica O, Kotecha D. Transforming clinical research by involving and empowering patients- the RATE-AF randomized trial. Eur Heart J 2021;42:2411-4. [PMID: 33655299 DOI: 10.1093/eurheartj/ehab098] [Reference Citation Analysis]
30 Stefil M, Lip GY. Atrial fibrillation. Medicine 2022;50:516-21. [DOI: 10.1016/j.mpmed.2022.05.007] [Reference Citation Analysis]
31 Minners J, Jander N. Consecutive, index and representative beats: obtaining reliable information despite an irregular heart rhythm. Heart 2021;107:862-3. [PMID: 33727256 DOI: 10.1136/heartjnl-2020-318923] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Zheng H. Cardiovascular Benefits of Digoxin and Empagliflozin in Patients with Chronic Heart Failure: The DIG Trial Revisited. Am J Med 2022;135:670-2. [PMID: 35235821 DOI: 10.1016/j.amjmed.2022.01.050] [Reference Citation Analysis]
33 Bunting KV, Gill SK, Sitch A, Mehta S, O'Connor K, Lip GY, Kirchhof P, Strauss VY, Rahimi K, Camm AJ, Stanbury M, Griffith M, Townend JN, Gkoutos GV, Karwath A, Steeds RP, Kotecha D; RAte control Therapy Evaluation in permanent Atrial Fibrillation (RATE-AF) trial group. Improving the diagnosis of heart failure in patients with atrial fibrillation. Heart 2021;107:902-8. [PMID: 33692093 DOI: 10.1136/heartjnl-2020-318557] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Guo Y, Kotalczyk A, Wang Y, Lip GYH. Digoxin use and clinical outcomes in elderly Chinese patients with atrial fibrillation: a report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. Europace 2022:euab319. [PMID: 35025995 DOI: 10.1093/europace/euab319] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Steurer J. Pe໿rmanentes Vorhofflimmern und Herzinsuffizienz: Digoxin scheint Bisoprolol etwas überlegen zu sein. Praxis (Bern 1994) 2021;110:227. [PMID: 33726511 DOI: 10.1024/1661-8157/a003641] [Reference Citation Analysis]